ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "remission and rheumatoid arthritis (RA)"

  • Abstract Number: 394 • 2012 ACR/ARHP Annual Meeting

    Remission After One Year in ACPA Positive and ACPA Negative Patients with Early Arthritis

    K.V.C. Wevers-de Boer1, L. Heimans1, K. Visser1, A.A. Schouffoer2, T.H.E. Molenaar3, J.B. Harbers4, C. Bijkerk5, I. Speyer6, M. de Buck7, P.B. de Sonnaville8, B.A. Grillet9, Tom Huizinga1 and C.F. Allaart1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Haga Hospital, The Hague, Netherlands, 3Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, 4Franciscus Hospital, Roosendaal, 5Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, 6Rheumatology, Bronovo Hospital, Den Haag, Netherlands, 7MCH, The Hague, 8Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, 9Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands

    Background/Purpose: To evaluate possible differences in clinical response after one year of remission steered treatment in Anti Citrullinated Protein Antibody (ACPA) positive and negative RA…
  • Abstract Number: 2606 • 2012 ACR/ARHP Annual Meeting

    Patient Reported Outcomes in Early Arthritis Patients

    L. Heimans1, K.V.C. Wevers-de Boer1, K. Visser1, R. Goekoop2, T.H.E. Molenaar3, B.A. Grillet4, Tom Huizinga1 and C.F. Allaart1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Haga Hospital, The Hague, Netherlands, 3Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, 4Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands

    Background/Purpose: To investigate patient reported outcomes (PROs) of functioning and health related quality of life (HRQOL) after 1 year remission (DAS
  • Abstract Number: 396 • 2012 ACR/ARHP Annual Meeting

    Prevalence, Concordance and Predictors of Early and Sustained Remission Assessed by Various Indices in the French Early Arthritis Espoir Cohort

    Cédric Lukas1, Ihsane Hmamouchi2, Xavier Le Loet3, Bruno Fautrel4 and Bernard Combe5, 1Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, 2El Ayachi Hospital, Rabat, Morocco, 3Rheumatology Department, CHU de ROUEN, Rouen, France, 4Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, 5Rheumatology, Hopital Lapeyronie, Montpellier, France

    Background/Purpose: Clinical remission is the best achievable state in patients with rheumatoid arthritis (RA). The definition of remission, however, is still under debate. The aim…
  • Abstract Number: 2608 • 2012 ACR/ARHP Annual Meeting

    Time in Remission Is Important for Improvement of Physical Function in Patients with Rheumatoid Arthritis (RA)

    Helga Radner1, Farideh Alasti2, Josef S. Smolen3 and Daniel Aletaha4, 1Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, 2Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 4Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Physical function is one of the major outcomes in RA as it predicts work disability, quality of life, health care resource utilisation and mortality.…
  • Abstract Number: 399 • 2012 ACR/ARHP Annual Meeting

    Can Sustained Remission of Rheumatoid Arthritis Be Predicted? an Analysis From the Japanese National Database of Rheumatic Disease (NinJa)

    Yoichiro Haji1, Mitsumasa Kishimoto1, Ryo Rokutanda1, Sachiko Ohde2, Gautam A. Deshpande3, Yuri Ohara1, Chisun Min1, Yasuhiro Suyama1, Hisanori Shimizu1, Ken-ichi Yamaguchi1, Akira Takeda4, Yukio Matsui1, Masato Okada1 and Shigeto Tohma5, 1Division of Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, 2Center for Clinical Epidemiology, St.Luke's Life of Science Institute, Tokyo, Japan, 3Center for Clinical Epidemiology, St. Luke's Life Science Instutute, Tokyo, Japan, 4Division of Clinical Immunology & Rheumatology, International University of Health and Welfare Hospital, Nasu-shiobara, Japan, 5Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan

    Background/Purpose: Achievement of clinical remission in rheumatoid arthritis (RA) is now the goal of therapy to reduce joint damage and disability, and maintain or improve…
  • Abstract Number: 2610 • 2012 ACR/ARHP Annual Meeting

    Predictors of Sustained Clinical Remissionin Early Rheumatoid Arthritis – Results From the Canadian Early Arthritis Cohort

    Bindee Kuriya1, Juan Xiong2, Gilles Boire3, Boulos Haraoui4, Carol A. Hitchon5, Janet E. Pope6, J. Carter Thorne7, Diane Tin8, Edward Keystone9, Vivian P. Bykerk10 and CATCH11, 1Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 2Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 3Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 4Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, 5University of Manitoba, Winnipeg, MB, Canada, 6Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, 7Southlake Regional Health Centre, Newmarket, ON, Canada, 8The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 9University of Toronto, Toronto, ON, Canada, 10Rheumatology, Hospital for Special Surgery, New York, NY, 11Dr. Vivian P. Bykerk, Toronto, ON, Canada

    Background/Purpose: Rapid time-to-remission has been associated with sustained remission in established rheumatoid arthritis (RA)1. However, the prevalence and predictive factors of sustained remission in early…
  • Abstract Number: 400 • 2012 ACR/ARHP Annual Meeting

    High Patient Global Assessment Scores Associate with the Residual Disease Activity Unidentified by a 28-Joint Examination in Rheumatoid Arthritis Patients Approaching Clinical Remission

    Yasushi Inoue1, Eiichi Tanaka2, Ayako Nakajima3, Eisuke Inoue4, Akiko Kobayashi4, Daisuke Hoshi1, Naoki Sugimoto4, Kumi Shidara4, Yohei Seto4, Atsuo Taniguchi4, Shigeki Momohara1 and Hisashi Yamanaka1, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Tokyo Women's Medical University, Tokyo, Japan, 3Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 4Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Background/Purpose: Patient global assessment (PtGA) is a component of the new ACR/EULAR remission criteria for rheumatoid arthritis (RA). It has been reported that >50% of…
  • Abstract Number: 2605 • 2012 ACR/ARHP Annual Meeting

    Exploration of Possible Preliminary Descriptions of Remission Based On RAPID3, without Laboratory Tests or Formal Joints Counts but with Careful Joint Examinations, in the Etude Et Suivi Des Polyarthrites Indifférenciées Récentes (ESPOIR) Cohort of Early Rheumatoid Arthritis Patients

    Isabel Castrejón1, Maxime Dougados2, Bernard Combe3, Bruno Fautrel4 and Theodore Pincus1, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 3Rheumatology, Hopital Lapeyronie, Montpellier, France, 4Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France

    Background/Purpose: Criteria for remission in rheumatoid arthritis (RA) have been developed according to DAS28 (disease activity score), CDAI (clinical disease activity index), and two recent…
  • Abstract Number: 404 • 2012 ACR/ARHP Annual Meeting

    Remission is a Difficult Target in Clinical Practice When RA Disease Is Established

    Till Uhlig1, Elisabeth Lie2, Cecillie Kaufmann3, Erik Rødevand4, Knut Mikkelsen5, Synnøve Kalstad6 and Tore K. Kvien1, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Rheumatology department, Vestre Viken, Drammen, Norway, 4Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, 5Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 6Dept. of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway

    Background/Purpose: Clinical remission is the treatment target in rheumatoid arthritis (RA) and several composite indices are available for evaluation of remission and low disease activity…
  • Abstract Number: 2140 • 2012 ACR/ARHP Annual Meeting

    A Longitudinal Study of Prognostic Factors in Patients with Early RA Providing Direction for Future Clinical Treatment- Predict Study

    Paul Bird1, David Nicholls2, Julien P. de Jager3, Hedley Griffiths4, Lynden Roberts5, Kathleen Tymms6, Jane Zochling7, Mark H. Arnold8, Geoffrey O. Littlejohn9 and OPAL Consortium10, 1Combined Rheumatology Practice, Sydney, Australia, 2Coast Joint Care, Maroochydore, Australia, 3Suite 2, Osler House, Southport, Australia, 4Barwon Rheumatology Service, Geelong, Australia, 5School of Medicine, James Cook University, Townsville, Australia, 6Canberra Rheumatology, Canberra, ACT, Australia, 7Menzies Research Institute Tasmania, Hobart, Australia, 8Orthopaedic Arthritis Spec Ctr, Level 2 The Gallery, Chatswood, Australia, 9Rheumatology, Monash Medical Center, Melbourne, Australia, 10Melbourne, Australia

    Background/Purpose: Despite the conspicuous increase in available treatment for rheumatoid arthritis [RA], and the shift to early, more aggressive management, there is a paucity of…
  • Abstract Number: 405 • 2012 ACR/ARHP Annual Meeting

    Frequencies of Boolean and Index Based ACR-EULAR Remissions Differ Slightly Depending On the Method of Patient Global Assessment

    Paul Studenic1, Josef S. Smolen1 and Daniel Aletaha2, 1Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 2Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Two definitions of remission have been put forward by the ACR and EULAR: a Boolean based, requiring swollen and tender joint counts (SJC, TJC),…
  • Abstract Number: 2105 • 2012 ACR/ARHP Annual Meeting

    Significant Correlation Between ACR/EULAR Remission Criteria and a Simplified Measure Using RAPID3 and Careful Joint Examination without a Formal Joint Count

    Martin J. Bergman1, Isabel Castrejón2 and Theodore Pincus2, 1Taylor Hospital, Ridley Park, PA, 2Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: Definitions for the classification of “remission” have been proposed by ACR/EULAR: Boolean and SDAI1 swollen joint can be performed without interfering with usual patient interactions,…
  • Abstract Number: 131 • 2012 ACR/ARHP Annual Meeting

    Subclinical Arthritis Visualised by Positron Emission Tomography and Macrophage Targeting Precedes Clinical Flare in Rheumatoid Arthritis Patients in DAS28 Remission

    Y.Y.J. Gent1, A.E. Voskuyl1, N. Ahmadi2, N. Hoetjes3 and C.J. van der Laken1, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2Radiology, VU University Medical Center, Amsterdam, Netherlands, 3Nuclear Medicine & PET research, VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Macrophages play an important role in the pathophysiology of Rheumatoid Arthritis (RA). Targeting of macrophages by (R)-[11C]PK11195 positron emission tomography (PET) has previously been successfully…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology